The short version of drug affinity complex fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Some evidence suggests that amphetamine may be more strongly modulated by ovarian sex hormones than other psychostimulants such as methylphenidate, which may result in relatively greater variability in drug response across the menstrual cycle. Although preliminary observational evidence suggests potential benefit from adjusting amphetamine doses according to menstrual cycle phases, randomized controlled trials have not evaluated this practice.
=== Stable isotopes === The first evidence for multiple isotopes of a stable (non-radioactive) element was found by J. J. Thomson in 1912/1913 as part of his exploration into the composition of canal rays (positive ions). Thomson channelled streams of ions through parallel magnetic and electric fields, measured their deflection by placing a photographic plate in their path, and computed their mass to charge ratio using a method that became known as the Thomson's parabola method. Each 'line' could be identified with a specific atomic weight, and therefore different elements and compounds could be identified. Thomson's initial paper in the Philosophical Magazine explains the technique used, but makes no comment on anomalous lines; however, in a talk given to the Royal Institution on 17 January 1913 Thomson identified "a line corresponding to an atomic weight 22, which can not be identified with the line due to any known gas". He went on to comment thatThe origin of this line presents many points of interest; there are no known gaseous compounds of any of the recognized elements which have this molecular weight. Again, if we accept Mendeleef's Periodic Law, there is no room for a new element with this atomic weight.The same lecture was then given to the Cambridge Philosophical Society on 27 January 1913, and later in the year Thomson presented his mature interpretation as the Royal Society's Bakerian Lecture.
=== Commercial Engineers & Body Builders Company Ltd (CEBBCO) === Commercial Engineers & Body Builders Company Ltd (CEBBCO), a Madhya Pradesh based manufacturer of tipplers, trailers, and specialized defence vehicles, was acquired by Jupiter Wagons Limited in a buyout of its organization in 2019 under a National Company Law Tribunal (NCLT) governed stressed asset sale. JWL latter on 29 June 2022, announced its reverse merger with CEBBCO. Therefore, with this, the company completed its listing on the bourses.
Other religions in India (and population in the 2011 census) are Sarnaism (4.96 million) and Gondi-Koyapunem (1.03 million) and Sari dharma (510,000). In 1951—India's first postcolonial census—the percentage breakdown of India's religions was: Hindu (84.1%), Muslims (9.8%), Christians (2.3%), Sikhs (1.9%), Buddhists (0.7%) and Jains (0.5%); sixty years later, in India's last census (2011), the percentages were: Hindus (79.8%), Muslims (14.2%), Christians (2.3%), Sikhs (1.7%), Buddhists (0.7%) and Jains (0.4%) In absolute numbers, during the period 1951–2011, India's religious groups grew in the following manner: Hindus (304 million to 966 million), Muslims (35 million to 172 million), Christians (8.3 million to 28 million), Sikhs (6.82 million to 20.83 million), Buddhists (2.67 million to 8.44 million) and Jains (1.66 million to 4.45 million). In the decade 1951–1961, the population growth by religions was: Hindus (20.7%), Muslims (32.7%), Christians (29%), Sikhs (10.3%), Buddhists (5.9%), Jains (3.7%); in the decade 2001–2011, the growth was: Hindus (16.7%), Muslims (24.7%), Christians (15.7%), Sikhs (16.1%), Buddhists (4.8%), and Jains (2.2%). All religions have registered declining growth rates. Birth rates, population growth, and access to education influence how communities mobilise politically to preserve their places of worship, to manage charitable trusts, and to protect their family laws. Differences in states' laws, especially those prohibiting religious conversion—usually from Hinduism to other faiths—colour the daily lives of minority communities.
== See also == Enterprise Architecture framework Enterprise Collaboration Architecture Enterprise Modelling Methodology/Open Distributed Processing (EMM/ODP) Reference model Triune Continuum Paradigm View model ISO/IEC JTC 1/SC 7
Sources: en.wikipedia.org
The split and pool synthesis (S&P synthesis) differs from traditional synthetic methods. The important novelty is the use of compound mixtures in the process. This is the reason of its unprecedentedly high productivity. Using the method one single chemist can make more compounds in a week than all chemists produced in the whole history of chemistry. The S&P synthesis is applied in a stepwise manner by repeating three operations in each step of the process:
== Mechanical characteristics == While many uses of ivory are purely ornamental in nature, it often must be carved and manipulated into different shapes to achieve the desired form. Other applications, such as ivory piano keys, introduce repeated wear and surface handling of the material. It is therefore essential to consider the mechanical properties of ivory when designing alternatives. Elephant tusks are the animal's incisors, so the composition of ivory is unsurprisingly similar to that of teeth in several other mammals. It is composed of dentine, a biomineral composite constructed from collagen fibers mineralized with hydroxyapatite. This composite lends ivory the impressive mechanical properties—high stiffness, strength, hardness, and toughness—required for its use in the animal's day-to-day activities. Ivory has a measured hardness of 35 on the Vickers scale, exceeding that of bone. It also has a flexural modulus of 14 GPa, a flexural strength of 378 MPa a fracture toughness of 2.05 MPam1/2. These measured values indicate that ivory mechanically outperforms most of its most common alternatives, including celluloid plastic and polyethylene terephthalate. Ivory's mechanical properties result from the microstructure of the dentine tissue. It is thought that the structural arrangement of mineralized collagen fibers could contribute to the checkerboard-like Schreger pattern observed in polished ivory samples. This is often used as an attribute in ivory identification.
== Virulence == Like other virulent bacteria, GBS harbors an important number of virulence factors (virulence factors are molecules produced by bacteria that enhance their capacity to infect and damage human tissues), the most important being the capsular polysaccharide (rich in sialic acid)and a pore-forming toxin, β-hemolysin.
He uses his new batteries to enlarge himself, but is deleted by the Deka Wing Cannon. Terry X is voiced by Kenji Hamada (浜田 賢二, Hamada Kenji). Kulernian Jellyfis (クラーン星人ジェリフィス, Kurān Seijin Jerifisu): A non-humanoid jellyfish-themed criminal from Planet Kulern who can take over human beings' nervous systems, which is forbidden by space law. He controls Ban, but Tetsu uses his own Super Electro Fist to briefly kill him, forcing Jellyfis off before Tetsu revives Ban with his Electro Fist technique. Jellyfis pilots the Kaijuki Million Missile in retaliation, but is deleted by Super Dekaranger Robo, which Agent Abrella takes advantage of to storm the Deka Base. Jellyfis is voiced by Kōzō Shioya (塩屋 浩三, Shioya Kōzō). Gimonian Angorl (ギモ星人アンゴール, Gimo Seijin Angōru): An anglerfish-themed criminal from Planet Gimo whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist in attacking the Deka Base via his personal Kaijuki, Abtrex, only to be deleted by the Deka Wing Cannon and Deka Bike Robo. Angorl is voiced by Keiichi Sonobe (園部 啓一, Sonobe Keiichi). Gedonian Uniga (ゲド星人ウニーガ, Gedo Seijin Unīga): A sea urchin–themed criminal from Planet Gedo and the inspiration behind the Igaroids whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist in attacking the Deka Base, only to be deleted by the Dekarangers. Uniga is voiced by Kazuya Nakai.
=== Tenerife === Upon landing on Tenerife, Humboldt and Bonpland were received by local officials and noted the distinctive flora of the island, including bananas, papaws, and ornamental plants. On June 20, before dawn,Bonpland an Humboldt departed with guides and mules for La Orotava, near the Teide volcano. They passed through San Cristébal, built on a basalt ridge around the Peak of Tenerife, and paused to inspect rocks, eventually arriving at La Laguna, the capital of Tenerife. After the climbing Humboldt and his party left La Laguna, traversing a landscape rich in plant diversity, including palms, orange trees, vines, and cacti. The region’s natural beauty was contrasted by socio-economic inequality, with land concentrated among a few wealthy planters and the indigenous population living in poverty. The group passed through Juan de la Rambla, Victoria, and Matanza, sites of both agricultural abundance and historical conflict with Spanish conquest in the fifteenth century. In La Orotava, they visited the botanical garden and met Monsieur LeGros, the French vice-consul, who had lived on Tenerife since being shipwrecked and agreed to guide their ascent of Pico del Teide. On 21 June 1799, the climbing party, which included LeGros, other local guides, and consular staff, departed for the volcano. The route passed solidly built but somber towns, lush gardens, and a renowned dragon tree, a species present in the Canaries but native to the West Indies, illustrating the complexities of plant distribution.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.